PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Makassed General Hospital, Beirut, Lebanon; Lebanese University, Beirut, Lebanon. Electronic address: moghniehrima@gmail.com.\', \'Makassed General Hospital, Beirut, Lebanon.\', \'Al-Zahraa University Hospital, Beirut, Lebanon.\', \'Senior Scientific Advisor, GAP Solutions (under Contract No. 75N93019D00026 with National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, United States of America); American University of Beirut, Beirut, Lebanon.\', \'American University of Beirut, Beirut, Lebanon.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0264-410X(21)01314-110.1016/j.vaccine.2021.10.007
?:doi
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 34656379
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
?:title
  • Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all